The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma

被引：33
作者：
Davidson, B. [1 ,2 ]
机构：
[1] Oslo Univ Hosp, Dept Pathol, Norwegian Radium Hosp, Div Pathol, N-0310 Oslo, Norway
[2] Univ Oslo, Fac Med, Oslo, Norway
来源：
CYTOPATHOLOGY | 2011年 / 22卷 / 01期
关键词：
cytology; malignant mesothelioma; serous carcinoma; effusion; diagnosis; cancer biology; COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL OVARIAN-CANCER; FOLATE RECEPTOR-ALPHA; PLEURAL MESOTHELIOMA; PERITONEAL MESOTHELIOMA; DIFFERENTIAL-DIAGNOSIS; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; LAMININ RECEPTOR; POOR SURVIVAL;
D O I：
10.1111/j.1365-2303.2010.00829.x
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma Malignant mesothelioma and ovarian/peritoneal serous carcinoma are two of the most common tumours affecting the serosal cavities. Unlike other malignant tumours diagnosed at this anatomical site, such as lung and breast carcinoma, malignant mesothelioma and serous carcinoma share a common histogenesis, may be difficult to differentiate morphologically, and co-express many of the diagnostic markers used by cytopathologists in effusion diagnosis. Selected markers have nevertheless shown sufficient sensitivity and specificity to differentiate serous carcinoma from malignant mesothelioma effectively. Recently, our group applied high throughput technology to the identification of new markers that may aid in differentiating these two cancer types and validated several of these markers in follow-up studies. This review will present current data regarding the diagnostic and biological aspects of malignant mesothelioma and ovarian/peritoneal serous carcinoma.
引用
收藏
页码：5 / 21
页数：17
相关论文
共 157 条
[1]   Problems in mesothelioma diagnosis [J].
Addis, Bruce ;
Roche, Heather .
HISTOPATHOLOGY, 2009, 54 (01) :55-68
[2]   The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant [J].
Aerts, J. G. J. V. ;
Delahaye, M. ;
Van der Kwast, T. H. ;
Davidson, B. ;
Hoogsteden, H. C. ;
Van Meerbeeck, J. R. .
DIAGNOSTIC CYTOPATHOLOGY, 2006, 34 (08) :523-527
[3]   Differentiation of mesothelioma from adenocarcinoma in serous effusions: The role of hyaluronic acid and CD44 localization [J].
Afify, AM ;
Stern, R ;
Michael, CW .
DIAGNOSTIC CYTOPATHOLOGY, 2005, 32 (03) :145-150
[4]   Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity [J].
Agarwal, R ;
D'Souza, T ;
Morin, P .
CANCER RESEARCH, 2005, 65 (16) :7378-7385
[5]  
[Anonymous], 2008, Global cancer facts figures
[6]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[7]   Utility of HBME-1 immunostaining in serous effusions [J].
Ascoli, V ;
CarnovaleScalzo, C ;
Taccogna, S ;
Nardi, F .
CYTOPATHOLOGY, 1997, 8 (05) :328-335
[8]   Malignant peritoneal mesothelioma in women - A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis [J].
Baker, PM ;
Clement, PB ;
Young, RH .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (05) :724-737
[9]  
Bang K. M., 2009, Morbidity and Mortality Weekly Report, V58, P393
[10]   D2-40 is not a specific marker for cells of mesothelial origin in serous effusions [J].
Bassarova, Assia V. ;
Nesland, Jahn M. ;
Davidson, Ben .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (07) :878-882
12345678910